Cancer medicine built for patients: stronger, simpler, and safer.
DUO is The New Chemo.
Duo Oncology is developing tumor-activated prodrug combinations designed to replace toxic multi-agent chemotherapy regimens with single medicines that concentrate therapeutic activity in tumors while limiting healthy-tissue exposure.
Duo's lead clinical-stage product, DUO-207, is designed to replace gemcitabine plus paclitaxel with a single-infusion, tumor-metabolized prodrug built to serve as a next-generation chemotherapy backbone for the KRAS inhibitor era in indications such as pancreatic cancer and lung cancer.
Company Snapshot
Clinical-stage prodrug company upgrading entire solid-tumor chemotherapy regimens.
Best-in-class tumor-activated chemistry supported by peer-reviewed publications and complete GLP toxicology.
Lead product starting adaptive Phase 1b/2 trial with enrollment across pancreatic, lung, and breast cancers.
Team of experienced oncology developers backed by BeOne Medicines, venture investors, NIH National Cancer Institute and Frederick National Laboratory.
Problem to Solution
Multi-agent chemotherapy remains the foundation or backbone of cancer care. Yet it is toxic, complicated, and costly. A new backbone would benefit:
Patients and Caregivers: Fewer and faster infusions, better quality of life, and less time feeling sick from treatment.
Hospitals and Clinics: Simpler dosing, fewer missed treatments, and a more usable backbone for modern combinations.
Payors and Pharma: Lower treatment burden, new targeted combinations and a scalable low, cost of goods from efficient pharmacology.
Lead Product DUO-207
DUO-207 combines gemcitabine and paclitaxel (GEM + PTX) into a single infusion, tumor-activated prodrug designed to strengthen tumor pharmacology, simplify treatment, and lower systemic exposure.
KRASi momentum makes the backbone matter: daraxonrasib has renewed focus on pancreatic cancer combinations built around GEM + PTX.
30+ KRAS inhibitors are advancing in pancreatic and lung cancer: winning combinations will need safer, more potent chemotherapy partners.
DUO-207 is built to be the new chemo: a next-generation GEM + PTX backbone designed to be stronger in tumor, simpler for clinics, and safer for patients.